# VCA-894A PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vca-894a

> The FDA approved VCA-894A, sponsored by Vanda Pharmaceuticals Inc. (VNDA), on Jan 2024 for patient with CMT2S.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VCA-894A |
| Codes | VCA-894A |
| Sponsor | Vanda Pharmaceuticals Inc. (VNDA) https://sec-api.dev/companies/vnda/catalysts |
| Indications | patient with cmt2s |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Jan 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: patient with CMT2S.
- First seen 2025-02-14, last confirmed 2026-02-12.
- SEC Form 10-K (accession 0001628280-26-007460): "In January 2024, we announced that the FDA had approved the IND application to evaluate VCA-894A for the treatment of a patient with CMT2S. CMT2S is a rare subtype of Charcot-Marie-Tooth disease (CMT), an inherited peripheral neuropathy for which there is no available treatment." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm
- SEC Form 10-K (accession 0001628280-25-005761): "In January 2024, we announced that the FDA had approved the Investigational New Drug (IND) application to evaluate VCA-894A for the treatment of a patient with CMT2S. CMT2S is a rare subtype of Charcot-Marie-Tooth disease (CMT), an inherited peripheral neuropathy for which there is no available treatment." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vca-894a.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VCA-894A PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vca-894a

```bibtex
@misc{secapidev_pdufa_vca_894a_20261116,
  title        = {VCA-894A PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vca-894a}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vca_894a_20261116","title":"VCA-894A PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vca-894a","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
